Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (51-60 of 302) with videos related to

Pageof 31
Sort By:
Future Science OA|June 28, 2019
New UPLC-MS/MS assay for the determination of tamoxifen and its metabolites in human plasma, application to patientsChristine Bobin-Dubigeon, Mario Campone, Elsa Rossignol, et al.
JCO Clinical Cancer Informatics|September 22, 2025
Hybrid ReGex and Natural Language Inference Model as a Zero-Shot Classifier for Extracting Data From Medical ReportsNicolas Wagneur, Olivier Capitain, Stéphane Supiot, et al.
Journal of Medical Economics|August 29, 2014
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western EuropeMario Campone, Hongbo Yang, Elizabeth Faust, et al.
Scientific Reports|June 19, 2024
Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblastsLisa Nocquet, Julie Roul, Chloé C Lefebvre, et al.
Bulletin Du Cancer|September 25, 2021
[Interest of the bc-GenExMiner web tool in oncology]Pascal Jézéquel, Wilfried Gouraud, Fadoua Ben Azzouz, et al.
Cancer Chemotherapy and Pharmacology|June 2, 2014
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumorsRuth Plummer, Peter Stephens, Louiza Aissat-Daudigny, et al.
Genome Medicine|November 9, 2021
Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genesAmandine Billaud, Louise-Marie Chevalier, Paule Augereau, et al.
Bulletin Du Cancer|January 7, 2004
[Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer]Mario Campone, Pierre Kerbrat, Henri Roché, et al.
Drugs in Context|November 24, 2017
Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII)Neon Brooks, Mario Campone, Silvia Paddock, et al.
Cancer Chemotherapy and Pharmacology|August 30, 2008
Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancerMario Campone, Maria Blasinska-Morawiec, Anna Tekiela, et al.
Pageof 31

Showing results (51-60 of 302) with videos related to

Sort By:
Pageof 31
Future Science OA|June 28, 2019
New UPLC-MS/MS assay for the determination of tamoxifen and its metabolites in human plasma, application to patientsChristine Bobin-Dubigeon, Mario Campone, Elsa Rossignol, et al.
JCO Clinical Cancer Informatics|September 22, 2025
Hybrid ReGex and Natural Language Inference Model as a Zero-Shot Classifier for Extracting Data From Medical ReportsNicolas Wagneur, Olivier Capitain, Stéphane Supiot, et al.
Journal of Medical Economics|August 29, 2014
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western EuropeMario Campone, Hongbo Yang, Elizabeth Faust, et al.
Scientific Reports|June 19, 2024
Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblastsLisa Nocquet, Julie Roul, Chloé C Lefebvre, et al.
Bulletin Du Cancer|September 25, 2021
[Interest of the bc-GenExMiner web tool in oncology]Pascal Jézéquel, Wilfried Gouraud, Fadoua Ben Azzouz, et al.
Cancer Chemotherapy and Pharmacology|June 2, 2014
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumorsRuth Plummer, Peter Stephens, Louiza Aissat-Daudigny, et al.
Genome Medicine|November 9, 2021
Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genesAmandine Billaud, Louise-Marie Chevalier, Paule Augereau, et al.
Bulletin Du Cancer|January 7, 2004
[Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer]Mario Campone, Pierre Kerbrat, Henri Roché, et al.
Drugs in Context|November 24, 2017
Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII)Neon Brooks, Mario Campone, Silvia Paddock, et al.
Cancer Chemotherapy and Pharmacology|August 30, 2008
Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancerMario Campone, Maria Blasinska-Morawiec, Anna Tekiela, et al.
Pageof 31